Financials

  • Market Capitalization 2.37 B
  • Employee 540
  • Founded 2008
  • CEO N/A
  • Website www.agios.com
  • Headquarter Delaware, United States
  • FIGI BBG000QY4ZD0
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-3.82
Price to sales ratio
29.21

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
1873
TARS
Tarsus Pharmaceuticals, Inc. - Common Stock
56.11 USD-5.40%-20.06%-9.69%-15.06%2.41 B USD
1880
NRIX
Nurix Therapeutics, Inc. - Common stock
22.98 USD+1.19%-4.29%+35.74%+105.00%2.38 B USD
1888
VCEL
Vericel Corporation - Common Stock
46.09 USD-2.95%-1.20%+19.96%+26.80%2.35 B USD
1901
NKTR
Nektar Therapeutics - Common Stock
67.17 USD-1.68%-9.23%+10.19%-8.33%2.27 B USD

Frequently asked questions about Agios Pharmaceuticals, Inc. - Common Stock

What is the Agios Pharmaceuticals, Inc. - Common Stock stock price today?

The current price of Agios Pharmaceuticals, Inc. - Common Stock (AGIO) is 39.92. Over the past 24 hours, the stock has changed by -1.55%. Follow the AGIO chart for real-time price dynamics.

What is the stock ticker of Agios Pharmaceuticals, Inc. - Common Stock?

Agios Pharmaceuticals, Inc. - Common Stock trades under the ticker AGIO. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Agios Pharmaceuticals, Inc. - Common Stock stock going up?

AGIO has changed by -8.78% over the last week, +24.83% over the last month, and -8.00% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Agios Pharmaceuticals, Inc. - Common Stock net income for the last quarter?

Agios Pharmaceuticals, Inc. - Common Stock reported net income of -99.11 M for the last quarter. The previous quarter showed -108.04 M, which means net income changed by +8.26%.

How many employees does Agios Pharmaceuticals, Inc. - Common Stock have?

As of the latest available data, Agios Pharmaceuticals, Inc. - Common Stock has 540 employees. Workforce size can provide additional context about the company's scale and operations.

What is Agios Pharmaceuticals, Inc. - Common Stock EBITDA?

Agios Pharmaceuticals, Inc. - Common Stock EBITDA is -109.81 M, and its EBITDA margin is -529.29%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Agios Pharmaceuticals, Inc. - Common Stock stock?

You can buy Agios Pharmaceuticals, Inc. - Common Stock (AGIO) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Agios Pharmaceuticals, Inc. - Common Stock stock?

Investing in Agios Pharmaceuticals, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the AGIO chart and related analysis on metatrader.com as part of your research.

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

News